



Committed to  
Excellence in  
*Cardiac &  
Diabetic care....*



# GOLDEN TRIO TO **LIVE LONG Life....**

# AOVA<sup>®</sup>-Gold **10/20**

Atorvastatin 10, 20mg + Clopidogrel 75mg + Aspirin 75mg **CAPSULES**



## ATORVASTATIN

- Lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of HMG-CoA reductase<sup>1</sup>

## CLOPIDOGREL

- Inhibits platelet aggregation; has beneficial effects in patients with acute coronary syndromes<sup>2</sup>

## ASPIRIN

- Prevents several vascular events including fatal and nonfatal MI, stroke & sudden cardiac death<sup>3</sup>


1.Clin Pharmacokinet. 2003;42(13):1141-60.

2.N Engl J Med. 2001 Aug 16;345(7):494-502.

3.Clin Med Res. 2014 Dec; 12(3-4): 147-154.

**ACUTE CORONARY SYNDROME  
MYOCARDIAL INFARCTION  
ANGINA || STROKE**





AGD  
AOF

# AOVA<sup>®</sup>-F

Atorvastatin 10mg + Fenofibrate 160mg **TABLETS**

Potential therapeutic option for better lipid profiles and minimizing the cardiovascular risk<sup>1</sup>

Effective in improving the overall patient outcome<sup>1</sup>

Significantly greater reduction in TG than those treated with atorvastatin alone<sup>2</sup>

Significantly greater reduction in non-HDL-C compared with fenofibrate alone and a greater increase in HDL-C compared with atorvastatin alone<sup>2</sup>

**MIXED DYSLIPIDEMIA**

**HYPERCHOLESTEROLEMIA**

**HYPERLIPIDEMIA**

**SEVERE HYPERTRIGLYCERIDEMIA**

ALSO  
AVAILABLE

**AOVA<sup>®</sup>** **10/20**

Atorvastatin 10, 20mg

**TABLETS**

1. Cureus. 2022 Mar; 14(3): e22852.

2. Clin Ther. 2009 Dec;31(12):2824-38.



**BISOXE<sup>®</sup>AM**

**Bisoprolol 5mg + Amlodipine 5mg TABLETS**

**BISOPROLOL**

$\beta$ -blocker drug<sup>1</sup>

**AMLODIPINE**

calcium channel blocker<sup>1</sup>

- Effective and convenient treatment for hypertension<sup>1</sup>
- Shows significant BP improvements in patients with essential hypertension following monotherapy failure<sup>2</sup>
- Shows high efficiency, good tolerance & increases patients compliance to the treatment<sup>3</sup>

**FOR THE TREATMENT OF HYPERTENSION**


**BISOXE<sup>®</sup> 2.5/5**  
**Bisoprolol 2.5, 5mg TABLETS**

1.Clin Pharmacol Drug Dev. 2017 Jan;6(1):9-18.

2.<https://doi.org/10.1080/03007995.2016.1205573>

3.Wiad Lek. 2014;67(2 Pt 2):326-7.





Conquer  
Hypertension for  
A Healthy  
Tomorrow.....

BAM  
BST

# BISOXE<sup>®</sup>-T

2.5	5
40	40

Bisoprolol 2.5/5mg + Telmisartan 40mg TABLETS

## BISOPROLOL

- Potent, highly selective beta-1 adrenergic blocker<sup>1</sup>
- Increases left ventricular function and reduces heart rate<sup>1</sup>

## TELMISARTAN


- Widely effective in patients with mild to moderate hypertension<sup>2</sup>
- Reduces BP along with favorable effects on blood glucose and heart rate<sup>2</sup>

**FOR THE TREATMENT OF ESSENTIAL HYPERTENSION**

1. Drugs. 2002;62(18):2677-96.

2. Bioinformation. 2021; 17(6): 652-659.





*Correct the  
Raised BP  
Level...*

# **Corsa<sup>®</sup>-T**

*Cilnidipine 10mg + Telmisartan 40mg* **TABLETS**

## **CILNIDIPINE**

- Calcium Channel Blocker; possesses both L- and N-type calcium channels blocking activity<sup>1</sup>
- Reduces the blood pressure through vascular smooth muscle relaxation and arterial dilatation<sup>2</sup>

## **TELMISARTAN**

- Angiotensin II receptor blocker; highly effective antihypertensive agent<sup>3</sup>
- Controls the early morning blood pressure surge more effectively than ramipril thus has a greater beneficial effect on long-term cardiovascular risk<sup>3</sup>

**TREATMENT OF ESSENTIAL HYPERTENSION**

**HYPERTENSION WITH DIABETES**

Also  
Available


**Corsa<sup>®</sup> 5/10**  
**Cilnidipine 5/10mg TABLETS**

1. Indian Heart J. 2013 Dec; 65(6): 691–695.

2. J Adv Pharm Technol Res. 2015 Apr-Jun; 6(2): 81–85

3. Vasc Health Risk Manag. 2006 Sep; 2(3): 195–201.





*Lessen Down the  
Sudden Rush  
in BP.....*

# Lanxes™-A

CST  
LXA

**Losartan Potassium 50mg + Amlodipine 5mg TABLETS**

**LOSARTAN:** Safe and effective in treating hypertensive patients with dyslipidemia<sup>1</sup>

**AMLODIPINE:** Provides enhanced cardiovascular protection compared with other antihypertensive agents<sup>2</sup>

**COMBINATION:** Effective and well-tolerated first line therapy for reducing blood pressure in stage 2 hypertensive patients<sup>3</sup>

**ANGINA**

**STAGE 1 & STAGE 2 HYPERTENSION  
UNCONTROLLED BY MONOTHERAPY**



**Lanxes™** **25  
50**  
**Losartan Potassium 25, 50mg TABLETS**

1.J Clin Diagn Res. 2017 Sep; 11(9): FC05-FC08.

2.Open Heart. 2016; 3(2): e000473

3.BMC Res Notes. 2011; 4: 461



Manage the  
Hypertension  
with Dual  
Action Of...

# Lanxes<sup>TM</sup>-H

**TABLETS**

Losartan potassium 50mg +  
Hydrochlorothiazide 12.5mg

## LOSARTAN

- Provides a more specific and complete blockade of the actions of angiotensin II than ACE inhibitors<sup>1</sup>
- Reduces the risk of future cardiovascular complications in hypertensive patients<sup>2</sup>
- Prevents more cardiovascular morbidity and mortality than atenolol<sup>2</sup>

## HYDROCHLOROTHIAZIDE

- Thiazide-type diuretic; acts on the distal convoluted tubules<sup>3</sup>

## HYPERTENSION

**HYPERTENSION WITH LEFT  
VENTRICULAR HYPERTROPHY (LVH)**

**INTOLERANCE TO ACEI**



**TABLETS**  
**Lanxes<sup>TM</sup> 25/50**  
Losartan Potassium 25/50mg


1. Drugs Aging. 2000 Mar;16(3):227-50. 2. J Clin Diagn Res. 2017 Sep; 11(9): FC05-FC08.  
3. <https://www.ncbi.nlm.nih.gov/books/NBK430766/>



# MEXES<sup>®</sup>-AM $\frac{25}{5}$ $\frac{50}{5}$

**Metoprolol Succinate 25, 50mg (PR) + Amlodipine Besilate 5mg**  
**TABLETS**

*Supply Maximum  
Protection  
To Heart.....*



## METOPROLOL

- More effective in sustained reduction of 24-hour and early morning blood pressure than atenolol<sup>1</sup>
- Reduces the risk of morbidity and mortality associated with CV diseases<sup>2</sup>

## AMLODIPINE

- First-line antihypertensive agent<sup>3</sup>
- Reduces ischemic episodes and anginal attacks & well tolerated in patients with stable angina pectoris<sup>4</sup>

LXH  
MAM

**HYPERTENSION**

**ANGINA PECTORIS**



**MEXES<sup>®</sup>-XL  $\frac{25}{50}$**   
**Metoprolol Succinate 25, 50mg (PR)**  
**TABLETS**

1.Saudi Med J. 2014; 35(11): 1307–1317

2.Iran J Pharm Res. 2016 Summer; 15(3): 561–566


3.Open Heart. 2016; 3(2): e000473.

4.J Cardiovasc Pharmacol. 1997 Apr;29(4):520-4.

**Act Three Dimensionally &  
Defeat Hypertension...**

# **MEXES<sup>®</sup>-3D**

**Metoprolol 25, 50mg (ER) + Telmisartan 40mg + Chlorthalidone 12.5mg  
TABLETS**



## **METOPROLOL**

- Greater reductions in early morning BP, heart rate & fractional pulse pressure than amlodipine in patients with hypertension<sup>1</sup>

## **TELMISARTAN**

- Highly effective antihypertensive agent<sup>2</sup>
- Reduces left ventricular hypertrophy, arterial stiffness & the recurrence of atrial fibrillation and confers renoprotection<sup>3</sup>

## **CHLORTHALIDONE**

- Thiazide-type diuretic for hypertension in patients at high risk of CVDs<sup>4</sup>
- Better 24-h BP control than HCTZ<sup>4</sup>

**FOR THE TREATMENT OF ESSENTIAL HYPERTENSION**

1. J Am Soc Hypertens. 2008 Sep-Oct;2(5):378-84

2. Vasc Health Risk Manag. 2006 Sep; 2(3): 195–201.

3. Expert Opin Pharmacother. 2011 Dec;12(17):2719-35.

4. J Hum Hypertens. 2019; 33(11): 766–774. CVDs: Cardio-Vascular Events

HCTZ: Hydrochlorothiazide



Ameliorate the **Blood Flow** to the Heart...



# NEXCORAN<sup>®</sup> 5

Nicorandil 5mg **TABLETS**

M3D  
NC5

- Well-known antianginal agent<sup>1</sup>
- Approved as a long-term therapy for chronic stable angina<sup>1</sup>
- Exhibits cardioprotective properties<sup>2</sup>
- Reduces risk of non-sustained ventricular & supraventricular arrhythmia when used in patients with unstable angina<sup>2</sup>
- Prevents myocardial ischemic reperfusion injury<sup>2</sup>
- Improves cardiac function without affecting BP as well as cardiac conduction or contraction<sup>2</sup>

**FOR THE PREVENTION AND LONG TERM  
TREATMENT OF ANGINA PECTORIS**

1. Indian J Pharmacol. 2019 Sep-Oct; 51(5): 296–301.

2. Cardiovasc Drugs Ther. 2016; 30(4): 367–378.





**NYFE<sup>®</sup> 2.6**

**Nitroglycerin 2.6mg (Controlled Release) TABLETS**

Possesses long-acting peripheral vasodilator action<sup>1</sup>

Alleviates anginal symptoms by decreasing myocardial oxygen consumption<sup>2</sup>

Provides statistically significant clinical improvement in angina<sup>3</sup>

Improves systolic & diastolic ventricular function by improving coronary flow in patients with ischemic cardiomyopathy<sup>4</sup>

**PROPHYLAXIS & LONG-TERM MANAGEMENT OF**  
**ANGINA PECTORIS ■ HEART FAILURE**  
**MYOCARDIAL INFARCTION**

1. Article first published online: 31 OCT 2013, DOI: 10.1002/clc.4960020104

2. Drug Des Devel Ther. 2015; 9: 4793–4805


3. J Am Coll Cardiol. 2017 Nov 7; 70(19): 2393–2410.

4. Cardiol Rev. 2010 Jul–Aug; 18(4): 190–197

Get **Out of the Severity** of Hypertension...

# Oukat<sup>®</sup>-AH **TABLETS**

Olmesartan Medoxomil 20mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg



## OLMESARTAN

Provides better antihypertensive efficacy than losartan & candesartan<sup>1</sup>

## AMLODIPINE

Shows anti-inflammatory and antioxidative effects<sup>2</sup>; effective for 24 hours BP control<sup>3</sup>

## HYDROCHLOROTHIAZIDE

Thiazide diuretic; effective in lowering blood pressure<sup>4</sup>

**NYF**  
**OAH**

**FOR THE TREATMENT  
OF ESSENTIAL  
HYPERTENSION**

1. Drugs June 2008, Volume 68, Issue 9, pp 1239-1272

2. Open Heart. 2016; 3(2): e000473.

3. J Assoc Physicians India. 2018 Mar;66(3):64-9

4. J Clin Hypertens (Greenwich). 2011 Dec; 13(12): 867-869.





Offer the **EXTREME CARE** to Heart...

**Oukat<sup>®</sup>-H**

Olmesartan Medoxomil 20mg +  
Hydrochlorothiazide 12.5mg **TABLETS**

**OLMESARTAN:**

- Angiotensin II receptor blocker; excellent efficacy in the reduction & stabilization of BP<sup>1</sup>
- More effective in lowering seated DBP than losartan, valsartan or irbesartan<sup>2</sup>

**HYDROCHLOROTHIAZIDE:**

- Diuretic and antihypertensive agent<sup>3</sup>

**COMBINATION:**

- Shows better effect on controlling BP & reducing the adverse events rate<sup>1</sup>

**Oukat<sup>®</sup> 20/40**  
Olmesartan Medoxomil 20/40mg  
**TABLETS**

Also Available

**FOR THE TREATMENT  
OF HYPERTENSION**

1. Cardiol Ther. 2017 Jun; 6(1): 13–32.

2. Drugs. 2002;62(9):1345-53; discussion 1354-6.


3. Med Arch. 2016 Jul 27; 70(4): 299–302.

# TWIST THE MENACE

## Linked To Hypertension...

# Tymist<sup>®</sup>-A

Telmisartan 40mg + Amlodipine 5mg **TABLETS**



- Provides superior BP-lowering efficacy<sup>1</sup>
- Safe efficacious option for the long-term treatment of hypertension<sup>2</sup>
- Significantly lowers the SBP and DBP compared to mono-therapies<sup>3</sup>
- Improved tolerability profile<sup>1</sup>

OKH  
TYM

**FOR MANAGEMENT OF  
HYPERTENSION**

Also  
Available


# Tymist<sup>®</sup> <sup>20</sup>/<sub>40</sub>

Telmisartan 20/40mg **TABLETS**

1. Drugs. 2011 Dec 3;71(17):2295-305.

2. Vasc Health Risk Manag. 2013; 9: 95-104.

3. J Clin Diagn Res. 2014 Jun; 8(6): HC08-HC11.



**Reduce the  
High Blood Pressure  
with Trusted  
Combination....**

# Tymist<sup>®</sup>-H

**Telmisartan 40mg + Hydrochlorothiazide 12.5mg TABLETS**

- Provides consistent 24-hour BP reductions throughout morning, daytime and night-time periods<sup>1</sup>
- Shows greater reduction in blood pressure than HCTZ with atenolol<sup>2</sup>
- Well-recognized clinical efficacy in the treatment of hypertension<sup>3</sup>
- Effective & well tolerated in patients with mild-to-severe hypertension<sup>4</sup>

**FOR THE TREATMENT OF HYPERTENSION**

**Tymist<sup>®</sup>** **20/40**  
**Telmisartan 20, 40mg TABLETS**


1. Drugs. 2008;68(13):1877-99.

2. Expert Opin Pharmacother. 2004 Nov;5(11):2303-10.

3. Vasc Health Risk Manag. 2007 Jun; 3(3): 265-278.

4. Expert Rev Cardiovasc Ther. 2013 Jun;11(6):673-82.





**Beat the  
Unhealthy  
State of  
Heart...**

# Tymist-Beta C <sup>25</sup>/<sub>50</sub>

**Telmisartan 40mg + Metoprolol 25/50mg (ER) + Cilnidipine 10mg  
TABLETS**

## TELMISARTAN

- An angiotensin II receptor blocker; has well-known antihypertensive property<sup>1</sup>
- Provides greater decreases in mean hourly systolic and diastolic blood pressure throughout the 24-hour dosing interval than amlodipine<sup>2</sup>

## METOPROLOL


- Reduces heart rate, blood pressure and mean arterial pressure<sup>3</sup>
- More effective in sustained reduction of 24-hour and early morning blood pressure than atenolol<sup>3</sup>

## CILNIDIPINE

- Reduces the blood pressure through vascular smooth muscle relaxation and arterial dilatation<sup>4</sup>

**TMH  
TBC**

# TREATMENT OF HYPERTENSION



**An Excellent Companion  
to Overcome  
the Raised BP....**

# **Tymist<sup>®</sup>-C** **TABLETS**

Telmisartan 40mg + Chlorthalidone 12.5mg

## **TELMISARTAN**

- Highly effective antihypertensive agent<sup>1</sup>
- Reduces left ventricular hypertrophy, arterial stiffness & the recurrence of atrial fibrillation and confers renoprotection<sup>2</sup>

## **CHLORTHALIDONE**

- Greater reduction in cardiovascular events than Hydrochlorothiazide<sup>3</sup>

**TREATMENT OF HYPERTENSION**

1.Vasc Health Risk Manag. 2006 Sep; 2(3): 195–201.

2.Expert Opin Pharmacother. 2011 Dec;12(17):2719-35.

3.J Hum Hypertens. 2019; 33(11): 766–774.



**Ensure Normal  
Blood Pressure  
for Better Life...**

# Tymist<sup>®</sup> Trio <sup>6.25</sup>/<sub>12.5</sub>

**Telmisartan 40mg + Cilnidipine 10mg + Chlorthalidone 6.25, 12.5mg TABLETS**

## **TELMISARTAN**

- Blocks the vasoconstrictor effects of angiotensin II; provides sustained 24-h BP control<sup>1</sup>

## **CILNIDIPINE**

- Calcium channel blocker; Improves left ventricular function<sup>2</sup>

## **CHLORTHALIDONE**

- Thiazide-type diuretic for hypertension in patients at high risk of CVDs<sup>3</sup>

**TMC**  
**TMT**


**FOR THE TREATMENT OF ESSENTIAL  
HYPERTENSION**

1. Cardiol Res. 2023 Jun; 14(3): 211–220.

2. Indian Heart J. 2013 Dec; 65(6): 691–695.

3. J Hum Hypertens. 2019; 33(11): 766–774.





**STOP** The Progression of  
Cardiovascular Problems....

**Ramsho<sup>®</sup>-H**

Ramipril 2.5mg + Hydrochlorothiazide 12.5mg **TABLETS**

**RAMIPRIL:**

- Angiotensin converting enzyme inhibitor<sup>1</sup>
- Improves cardiovascular prognosis of patients at high cardiovascular risk<sup>1</sup>
- Decreases rates of death, myocardial infarction and stroke<sup>2</sup>

**HYDROCHLOROTHIAZIDE:**

- Leads to the reduction in peripheral resistance and thus blood pressure<sup>3</sup>

**COMBINATION:**

- Shows greater reductions in supine systolic and diastolic blood pressures than ramipril alone<sup>4</sup>

**HYPERTENSION**

**HEART FAILURE**

**POST MYOCARDIAL  
INFARCTION**

Also Available:

**Ramsho<sup>®</sup>**  
Ramipril 5mg **TABLETS**

*When the Heart Needs  
Proper Maintenance...*

# RV-STAT™ Gold

**Rosuvastatin 10mg + Clopidogrel 75mg +  
Aspirin 75mg CAPSULES**



**ROSUVASTATIN:** More effective in reducing LDL cholesterol, sLDL cholesterol, total cholesterol/HDL cholesterol ratio and non-HDL cholesterol than atorvastatin<sup>1</sup>

**CLOPIDOGREL:** Inhibits platelet aggregation; has beneficial effects in patients with acute coronary syndromes<sup>2</sup>

**ASPIRIN:** Prevents several vascular events including fatal and nonfatal MI stroke & sudden cardiac death<sup>3</sup>

**FOR THE TREATMENT OF**  
**ACUTE CORONARY SYNDROME**  
**MYOCARDIAL INFARCTION — ANGINA — STROKE**

RAM  
RVS

1. Drug Healthc Patient Saf. 2009; 1: 25–33.

2. N Engl J Med. 2001 Aug 16;345(7):494–502.

3. Clin Med Res. 2014 Dec; 12(3–4): 147–154.  
HDL: High-Density Lipoprotein

sLDL: Small Dense Low-Density Lipoprotein





WHEN THERE IS A  
NEED TO CONTROL THE  
**Heightened  
Cholesterol Level...**

# RV-STAT™-TG

Rosuvastatin 10mg + Fenofibrate 160mg **TABLETS**

## ROSUVASTATIN

- Second-generation HMG-CoA reductase inhibitor; demonstrates lipid-lowering effect with a good tolerability profile<sup>1</sup>
- Produces greater reductions in LDL-C, ApoB and total cholesterol when compared with atorvastatin<sup>2</sup>

## FENOFIBRATE

- Effectively reduces postprandial VLDL and LDL particle concentrations<sup>3</sup>
- Reduces the increased oxidative stress and inflammatory response that occurs after a fatty meal<sup>3</sup>

**HYPERLIPIDEMIA**

**MIXED DYSLIPIDEMIA**

Also  
Available

**RV-STAT™** **5/10**  
Rosuvastatin 5/10mg **TABLETS**





Get Back the  
Diabetes-Free  
**Healthy Life...**

**DIGLA-M<sup>®</sup>** **10/500** **10/1000**

Dapagliflozin 10mg + Metformin HCl 500, 1000mg (ER) **TABLETS**

**DAPAGLIFLOZIN**

- Antihyperglycemic drug that selectively inhibits SGLT2<sup>1</sup>
- Reduces renal glucose reabsorption, leading to urinary glucose excretion and a reduction in blood glucose levels<sup>2</sup>

**METFORMIN:** Reduces serum glucose level by nonpancreatic mechanisms without increasing insulin secretion<sup>3</sup>

**COMBINATION:** Well tolerated and effective in reducing HbA1c, FPG & weight<sup>4</sup>


**TYPE-II DIABETES MELLITUS**

**RTG  
DAM**



**DIGLA-10<sup>®</sup>**  
Dapagliflozin 10mg **TABLETS**

1. Ther Adv Drug Saf. 2014 Dec; 5(6): 242-254.  
2. Drugs. 2012 Dec 3; 72(17): 2289-312.  
3. J Res Med Sci. 2014 Jul; 19(7): 658-664.  
4. Int J Clin Pract. 2012 May; 66(5): 446-56.  
HbA1c: Glycated Hemoglobin  
FPG: Fasting Plasma Glucose



**DEFEAT THE EARLY  
AS WELL AS  
Long-Standing  
Diabetes.....**

# **DIGLA<sup>®</sup>-GM $\frac{1}{2}$**

**Dapagliflozin 10mg + Metformin 500mg (ER) + Glimepiride 1, 2mg TABLETS**

## **DAPAGLIFLOZIN + METFORMIN**

- Beneficial to treat T2DM, especially for patients with severe uncontrolled hyperglycemia<sup>1</sup>
- Improves patient satisfaction and increases adherence<sup>1</sup>
- Provides additional reduction in blood glucose concentrations with the added benefit of modest weight loss and reduction in systolic blood pressure<sup>1</sup>

## **GLIMEPIRIDE**

- Effective in reducing fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels<sup>2</sup>

**TYPE-II DIABETES MELLITUS**

1. Diabetes Metab Syndr Obes. 2016; 9: 25–35.

2. Vasc Health Risk Manag. 2012; 8: 463–472.



**PERFECT ANSWER**  
**For Uncontrolled**  
**Diabetes.....**



**GADZ**



**GADZ<sup>®</sup> 1/2**  
**Glimepiride 1/2mg TABLETS**

Ameliorates the relative insulin secretory deficit found in patients with Type 2 DM<sup>1</sup>

Controls blood glucose level throughout the day through its effect on stimulating insulin release<sup>2</sup>


More effective than metformin in reducing postprandial blood glucose<sup>2</sup>

Shows fewer cardiovascular effects than other SUs<sup>2</sup>

**ADJUNCT TO DIET AND EXERCISE TO IMPROVE  
GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS**

**DGM  
GDZ**





**Cure**  
the Uncontrolled Diabetes  
with Dual Efficacy...

# LIBURE<sup>®</sup>-D **5/10**

Linagliptin 5mg + Dapagliflozin 10mg **TABLETS**

## LINAGLIPTIN

- Stimulates the release of insulin and decreases circulating levels of glucagon<sup>1</sup>
- Leads to an overall improvement in glucose homeostasis both in the fasting and post-prandial state<sup>2</sup>

## DAPAGLIFLOZIN

- Potent, highly selective SGLT2 inhibitor with proven efficacy and safety in patients with type 2 diabetes mellitus<sup>3</sup>

# TYPE-II DIABETES MELLITUS

1. P.T. 2011 Dec; 36(12): 807-812, 842

2.Clin Med Insights Endocrinol Diabetes. 2015; 8: 1-6.

3.Drugs. 2019; 79(10): 1135-1146.

**Perfect Combination for Diabetic Patient**  
**who Fail with Monotherapy.....**

# LIBURE<sup>®</sup>-EM

**5/25**  
**500, 1000**

**Linagliptin 5mg + Empagliflozin 25mg + Metformin 500, 1000mg TABLETS**



## **LINAGLIPTIN**

- Increases the biosynthesis of insulin and its secretion from pancreatic beta cells in presence of elevated levels of blood glucose<sup>1</sup>
- Provides prolonged inhibition of the DPP-4 enzyme (more than 80% at 24 hours after dosing)<sup>1</sup>

## **EMPAGLIFLOZIN**

- Effectively lowers fasting blood glucose, postprandial blood glucose, average daily glucose levels, glycated hemoglobin A1C (HbA1C) and also leads to significant weight reduction in patients with T2DM2

## **METFORMIN**

- Lowers plasma glucose without affecting insulin secretion<sup>3</sup>

1. P.T. 2011 Dec; 36(12): 807-812, 842    2. Biomedicines. 2022 Dec 19;10(12):3294.    3. Vasc Health Risk Manag. 2008 Jun; 4(3): 481-492.

**TYPE-2 DIABETES MELLITUS**

**LIB**  
**LEM**

*Liberate the Patient From  
the Load Of Diabetes...*



# LIBURE<sup>®</sup>-M

Linagliptin 2.5, 5mg + Metformin 500, 1000mg **TABLETS**

## LINAGLIPTIN:

- Oral antidiabetic drug that acts by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4)<sup>1</sup>
- Beneficial effects on cardiovascular and renal safety profiles in patients with type 2 diabetes<sup>2</sup>

## METFORMIN:

- Anti-hyperglycemic drug<sup>3</sup>
- Decreases hyperinsulinemia, improves lipid profiles and enhances endothelial function<sup>4</sup>

## TYPE-2 DIABETES MELLITUS

1. Ther Adv Endocrinol Metab. 2012 Aug; 3(4): 113–124.

2. Drugs. 2014 Oct; 74(16):1927–1946.

3. Front Endocrinol (Lausanne). 2020; 11: 191.

4. Res Med Sci. 2014 Jul; 19(7): 658–664.

LIBURE<sup>®</sup>-M


Linagliptin 2.5, 5mg **TABLETS**



*Say Good-Bye to  
Uncontrolled Diabetes.....*

# MATCE<sup>®</sup>-ER

Metformin 500, 1000mg (SR) **TABLETS**



Glucose-lowering agent<sup>1</sup>

Decreases blood sugar that liver produces and intestines absorb<sup>2</sup>


Shows cardiovascular protective effects independent of glucose-lowering effects<sup>1</sup>

Reduces the risk of all-cause mortality and acute myocardial infarction in overweight patients with T2DM<sup>1</sup>

**TYPE-II DIABETES  
MELLITUS**

1. Drug Des Devel Ther. 2017; 11: 2421–2429.

2. J Res Med Sci. 2014 Jul; 19(7): 658–664.



**DEAL WITH  
DIABETES  
Related Woes.....**

# MATCE<sup>®</sup>-G Forte

**Metformin 1000mg (SR) + Glimepiride 1/2/3mg TABLETS**

**METFORMIN:** Stimulates GLP-1 release, thereby enhancing insulin secretion and lowering plasma glucose levels<sup>1</sup>

**GLIMEPIRIDE:** Effective in reducing FPG, PPG and HbA1c<sup>2</sup>

**COMBINATION:** Highly effective in controlling blood glucose and improving glycated hemoglobin levels than if used as monotherapy<sup>3</sup>

**TYPE 2 DIABETES MELLITUS**

# MATCE<sup>®</sup>-G<sub>1/2/3</sub>

**Metformin 500mg (SR) + Glimepiride 1/2/3mg**

**BILAYERED MINI TABLETS** 

1.Front Endocrinol (Lausanne). 2020; 11: 191.

2.Vasc Health Risk Manag. 2012; 8: 463–472.  
GLP: Glucagon-like-peptide-1

HbA1c: Glycated hemoglobin levels

3.Cureus. 2021 Jan; 13(1): e13020.



**IMPROVE  
THE HEALTH  
STATUS  
DURING DIABETES**



MGF  
MGZ

# MAT<sup>CE</sup>-GZ

Metformin 500mg (SR) + Gliclazide 80mg **TABLETS**

## METFORMIN

- Anti-diabetic drug; used for the treatment of type 2 diabetes mellitus<sup>1</sup>
- First choice to treat T2D due to its remarkable ability to decrease plasma glucose levels<sup>2</sup>

## GLICLAZIDE

- Stimulates insulin secretion from pancreatic  $\beta$ -cells by inhibiting ATP-dependent potassium channels<sup>3</sup>
- Shows good effectiveness and tolerability profile in terms of low risk of hypoglycemia and weight gain, cardiovascular neutrality and long-term reduction of end-stage kidney disease<sup>4</sup>

1. J Res Med Sci. 2014 Jul; 19(7): 658–664.

2. Front Endocrinol (Lausanne). 2020; 11: 191.

3. Profiles Drug Subst Excip Relat Methodol. 2017;42:125–192.

4. Drugs Real World Outcomes. 2020 Dec; 7(4): 271–279.

**TYPE-2 DIABETES UNCONTROLLED BY MONOTHERAPY**  
**DIABETES IN ELDERLY**  
**DIABETES WITH VASCULAR COMPLICATIONS**





*Live the Life Happily*  
**WITHOUT THE  
BURDEN OF DIABETES....**

**MATCE<sup>®</sup>-PG1/2**  
Metformin 500mg (ER) + Pioglitazone 15mg + Glimepiride 1/2mg  
**TABLETS**

**METFORMIN:** First-line therapy for patients with T2DM<sup>1</sup>

**PIOGLITAZONE:** Shown to be effective in glycemic control by lowering insulin resistance<sup>2</sup>

**GLIMEPIRIDE:** Achieves & maintains good glycemic control in patients with type 2 diabetes<sup>3</sup>

**ADJUNCT TO DIET AND  
EXERCISE TO IMPROVE  
GLYCEMIC CONTROL IN  
TYPE 2 DIABETES MELLITUS**

1. Drug Des Devel Ther. 2017; 11: 2421–2429.

2. Clin Med Insights Endocrinol Diabetes. 2010; 3: 43–51.

3. Clin Ther. 2003 Mar;25(3):799-816



MVF  
MVG

# MATCE<sup>®</sup>-VG<sup>0.2/1</sup><sub>0.2/2</sub> **Forte**

Metformin 1000mg (SR) + Voglibose 0.2mg + Glimepiride 1, 2mg  
**TABLETS**

**METFORMIN:** Safe and effective in lowering glucose levels<sup>1</sup>

**VOGLIBOSE:** More potent and tolerant  $\alpha$  glucosidase inhibitor ( $\alpha$ -GI) as compared to Acarbose and Miglitol<sup>2</sup>

**GLIMEPIRIDE:** Second-generation sulfonylurea that stimulates pancreatic  $\beta$  cells to release insulin<sup>3</sup>

## TYPE 2 DIABETES MELLITUS

**ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL**



MATCE<sup>®</sup>-VG<sup>0.2/1</sup><sub>0.2/2</sub>  
Metformin 500mg (SR) + Voglibose 0.2mg + Glimepiride 1, 2mg **BILAYERED MINI TABLETS**

1.JAMA. 2019 May 21;321(19):1926-1927.

2. J Clin Diagn Res. 2013 Dec; 7(12): 3023-3027.

3.Vasc Health Risk Manag. 2012; 8: 463-472.

**KEEP THE**

**ENHANCED**

**GLUCOSE  
LEVEL**

**UNDER CONTROL....**

UNDER

Control

option

# MATCE<sup>®</sup>-VG $\frac{0.3/1}{0.3/2}$ *Forte*

**Metformin 1000mg (SR) + Voglibose 0.3mg + Glimepiride 1,2mg  
BILAYERED TABLETS**

**METFORMIN:** Anti-hyperglycemic drug, decreases the incidence of CVD in diabetes patients<sup>1</sup>

**VOGLIBOSE:** Effective & well tolerated in a wide range of Type 2 diabetic mellitus patients<sup>2</sup>

**GLIMEPIRIDE:** Ameliorates the relative insulin secretory deficit found in most patients with Type 2 DM<sup>3</sup>

**ADJUNCT TO DIET AND EXERCISE TO  
IMPROVE GLYCEMIC CONTROL  
IN TYPE 2 DIABETES MELLITUS**

Also  
Available

**MATCE<sup>®</sup>-VG  $\frac{0.3/1}{0.3/2}$**   
**Metformin 500mg (SR) + Voglibose 0.3mg +  
Glimepiride 1, 2mg BILAYERED MINI TABLETS**

1.Front Endocrinol (Lausanne). 2020; 11: 191.

2.J Clin Diagn Res. 2013 Dec; 7(12): 3023–3027.

3.Expert Opin Pharmacother. 2001 Apr;2(4):699-713.



*Bring Back the  
Lost Sweetness  
in Life Again...*



**POKR<sup>®</sup>** **15/30**

Pioglitazone 15/30mg **TABLETS**

**MAT**  
**POK**

Insulin sensitising thiazolidinedione agent<sup>1</sup>

Decreases HbA1c and fasting blood glucose levels significantly in patients with poorly controlled type 2 diabetes mellitus<sup>1</sup>


Reduces the risk of recurrent stroke significantly in high-risk patients with T2D<sup>2</sup>

**ADJUNCT TO DIET AND EXERCISE TO  
IMPROVE GLYCEMIC CONTROL IN  
TYPE 2 DIABETES MELLITUS**

1.Drugs. 2000 Aug;60(2):333-43; discussion 344-5.

2.Drugs. 2000 Aug;60(2):333-43; discussion 344-5.

3.Clin Med Insights Endocrinol Diabetes. 2010; 3: 43-51.



# SUZONE<sup>®</sup>-D **10/100**

Sitagliptin 100mg + Dapagliflozin 10mg  
**TABLETS**

## SITAGLIPTIN

- Potent, highly selective oral DPP-4 inhibitor<sup>1</sup>
- Useful in pre-diabetic stages and early stages of type 2 diabetes to retard or prevent the disease progression<sup>2</sup>

## DAPAGLIFLOZIN

- Increases the amount of glucose excreted in the urine and improves both fasting (FPG) and post-prandial plasma glucose levels<sup>3</sup>

**FOR THE TREATMENT OF TYPE-II DIABETES MELLITUS**

1.P.T. 2012 Dec; 37(12): 699–708.

2.Vasc Health Risk Manag. 2007 Apr; 3(2): 203–210.

3.Drugs. 2019; 79(10): 1135–1146.

# Get Positive Outcomes in One Formula...

**SUZONE<sup>®</sup>-DM** **100/500** **100/1000**  
**Sitagliptin 100mg + Dapagliflozin 10mg + Metformin (ER) 500, 1000mg**  
**TABLETS**

**SITAGLIPTIN:** Stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion<sup>1</sup>


- Improves beta-cell function<sup>1</sup>

**DAPAGLIFLOZIN:** Increases the amount of glucose excreted in the urine and improves both fasting (FPG) and post-prandial plasma glucose levels<sup>2</sup>

**METFORMIN:** Prevents diabetes in people who are at high risk and decreases most of the diabetic complications<sup>3</sup>

SUZ  
SDM

1.Vasc Health Risk Manag. 2007 Apr; 3(2): 203–210. 2.Drugs. 2019; 79(10): 1135–1146.  
3.J Res Med Sci. 2014 Jul; 19(7): 658–664.



**TYPE-2 DIABETES  
MELLITUS**



# SUZONE<sup>®</sup>-M **50** **500** **50** **1000**

Sitagliptin 50mg + Metformin 500, 1000mg  
**TABLETS**



1.P.T. 2012 Dec; 37(12): 699-708.

2.Vasc Health Risk Manag. 2007 Apr; 3(2): 203-210.

3.J Res Med Sci. 2014 Jul; 19(7): 658-664.

4.J Diabetes. 2017 Apr;9(4):412-422

5.P.T. 2012 Dec; 37(12): 699-708

## SITAGLIPTIN:

- Potent, highly selective oral DPP-4 inhibitor<sup>1</sup>
- Stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion<sup>2</sup>

**METFORMIN:** Activates the enzyme adenosine monophosphate kinase (AMPK) resulting in the inhibition of key enzymes involved in gluconeogenesis in the liver<sup>3</sup>

## COMBINATION:

- Shows significantly greater improvements in glycemic control and body weight changes than Glimepiride<sup>4</sup>
- More quickly and greater reductions of HbA1c and fasting plasma glucose levels than metformin alone<sup>5</sup>

## TYPE-2 DIABETES MELLITUS



SUZONE<sup>®</sup>- **50** **100** Sitagliptin 50, 100mg  
**TABLETS**

*Ensure the  
Victory  
Over  
Diabetes...*



# TACIA<sup>®</sup>-M

Teneligliptin 20mg + Metformin 500/1000mg  
(Sustained Release) **BILAYERED TABLETS**

SZO  
TAC

## TENELIGLIPTIN

- Significantly improves the glycemic control & well tolerated<sup>1</sup>
- More potent than voglibose or vildagliptin based on its glucose-lowering effects<sup>1</sup>

## METFORMIN

- Has the ability to improve glucose metabolism<sup>2</sup>
- Reduces the incidence of cardiovascular diseases in T2D patients<sup>2</sup>

**TYPE 2 DIABETES MELLITUS**


Also  
Available

**TACIA<sup>®</sup> 20**  
Teneligliptin 20mg **TABLETS**

1. Diabetes Metab Syndr Obes. 2016; 9: 251–260.  
2. Front Pharmacol. 2020; 11: 635.



## Excellent Duo to Tackle the Diabetic Complications...



**Venga-D<sup>®</sup>  $\frac{10}{100}$**   
Vildagliptin 100mg (SR) + Dapagliflozin 10mg **TABLETS**

### VILDAGLIPTIN

- Glucose-lowering agent<sup>1</sup>
- Improves glucose control in patients with mild to moderate hyperglycemia as a monotherapy or as an addition to other antidiabetic agents<sup>1</sup>
- Effectively improves glycemic control, preserves both the  $\alpha$ - and  $\beta$ -cell function and reduces lipotoxicity and insulin resistance<sup>1</sup>

### DAPAGLIFLOZIN

- Useful treatment option in the management of type 2 diabetes<sup>2</sup>
- Blocks reabsorption of filtered glucose in the kidney, increases urinary glucose excretion and reduces blood glucose levels<sup>3</sup>


**TYPE-II DIABETES MELLITUS**

1.Ther Clin Risk Manag. 2013; 9: 247–257.

2.Drugs. 2014 Dec;74(18):2191-209.

3.Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43.





**Ensure Sweet Triumph  
Over Diabetes with  
Triple Efficacy of....**

**VENGA<sup>®</sup>-DM  $\frac{100}{500}$   $\frac{100}{1000}$**

**Vildagliptin 100mg (SR) + Dapagliflozin 10mg + Metformin 500, 1000mg (SR) TABLETS**

#### **VILDAGLIPTIN**

- Enhances pancreatic islet function; improves glycemic control<sup>1</sup>

#### **DAPAGLIFLOZIN**

- Promotes glucose filtration through the kidneys into urine<sup>2</sup>
- Diminishes reabsorption of glucose into the bloodstream<sup>2</sup>

#### **METFORMIN**

- Lowers plasma glucose without affecting insulin secretion<sup>1</sup>

**VEN  
VDM**

**TYPE-II DIABETES MELLITUS**

**TURN DOWN**  
the Fasting & Postmeal  
Sugar Levels.....



# Venga<sup>®</sup>-Met $\frac{500}{1000}$

Vildagliptin 50mg + Metformin 500, 1000mg **TABLETS**

## VILDAGLIPTIN

- ▣ Antidiabetic agent, enhances pancreatic islet cell responsiveness to glucose<sup>1</sup>
- ▣ More potent than other DPP-4 inhibitor (sitagliptin) in suppressing glucagon and causes less glycemic variation<sup>2</sup>

## METFORMIN

- ▣ Exerts anti-hyperglycemic effects by suppressing hepatic glucose production through AMPK-dependent or -independent pathways<sup>3</sup>

## COMBINATION

- ▣ Effective therapy in reducing HbA1c that helps in achieving target glycemic control & well tolerated<sup>4</sup>

## TYPE 2 DIABETES MELLITUS

## TYPE 2 DIABETES UNCONTROLLED BY MONOTHERAPY

1. Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.  
2. Ther Clin Risk Manag. 2013; 9: 247-257.  
3. Front Endocrinol (Lausanne). 2020; 11: 191.  
4. Bioinformation. 2021; 17(3): 413-423.



Venga<sup>®</sup>  $\frac{50}{100SR}$

Vildagliptin 50, 100mg (SR) **TABLETS**



# V-GLIB<sup>®</sup>-MD 0.2 0.3

*Voglibose 0.2, 0.3mg* **MOUTH DISSOLVING TABLETS**

An  $\alpha$ -glucosidase inhibitor; used in the management of type 2 diabetes<sup>1</sup>

Delays the absorption of carbohydrates due to competitive inhibition of  $\alpha$ -glucosidase in the small intestine<sup>1</sup>

Inhibits the postprandial increase in plasma glucose levels, leads to decreased diurnal insulin secretion<sup>1</sup>

More potent and tolerant  $\alpha$  glucosidase inhibitor ( $\alpha$ -GI) as compared to Acarbose and Miglitol<sup>2</sup>

VMT  
VLM

**FOR MANAGEMENT OF**  
**POSTPRANDIAL HYPERGLYCEMIA IN DIABETES MELLITUS**

1.Int J Clin Pharmacol Ther. 2015 Feb; 53(2): 147–153.

2.J Clin Diagn Res. 2013 Dec; 7(12): 3023–3027.



Don't Let the High Blood Sugar Level Win,  
Take Action Today With....

**WinEmfa<sup>TM</sup>-M** **5,12.5**  
**500**

Empagliflozin 5, 12.5mg + Metformin Hcl 500mg (IR) **TABLETS**

#### EMPAGLIFLOZIN

- Oral glucose-lowering drug<sup>1</sup>
- An inhibitor of the sodium-glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion; contributes to improved glycemic control, reduced glucotoxicity and insulin resistance<sup>1</sup>
- Stronger impact on HbA1c reduction and leads to more weight loss compared to Dapagliflozin
- Shows superior cardiovascular protection & greater reduction in heart failure hospitalization than dapagliflozin

#### METFORMIN

- Decreases blood sugar that liver produces and intestines absorb<sup>2</sup>



**TYPE-2 DIABETES  
MELLITUS**

**WinEmfa<sup>TM</sup>10**  
Empagliflozin 10mg **TABLETS**

1. Biomedicines . 2022 Dec 19;10(12):3294.  
2. J Res Med Sci. 2014 Jul; 19(7): 658–664.

# Maximize The Nerve Health With....

# Malzix<sup>®</sup>-DN

**Methylcobalamin 1500mcg + ALA 100mg + Benfotiamine 100mg + Folic Acid 1.5mg +  
Pyridoxine HCl 3mg SOFTGEL CAPSULES**


**METHYLCOBALAMIN:** Has the ability to promote the injured nerves regeneration<sup>1</sup>

**ALPHA LIPOIC ACID:** Reduces the pain, paresthesias and numbness in patient with diabetic neuropathy<sup>2</sup>

**FOLIC ACID:** Improves the sciatic function index, nerve conduction velocity and cell proliferation<sup>3</sup>

**PYRIDOXINE:** Important for myelin formation<sup>4</sup>

**BENFOTIAMINE:** Significantly improves the symptoms of diabetic neuropathy in diabetes mellitus patients<sup>5</sup>



- DIABETIC NEUROPATHY
- DRUG/ALCOHOL INDUCED NEUROPATHY
- DIABETES/DYSLIPIDEMIA
- CARDIOVASCULAR COMPLICATIONS

WEM  
MDN

1. Neural Plast. 2013; 2013: 424651.  
2. Rev Diabet Stud. 2009 Winter; 6(4): 230–236.  
3. Neural Regen Res. 2019 Jan; 14(1): 132–139.  
4. CNS Neurosci Ther. 2020 Jan; 26(1): 5–13.



*When Neuropathic  
Pain **Starts**  
Torturing the  
Patient...*



**Malzix<sup>®</sup>-GB**

Methylcobalamin 500mcg + Gabapentin 300mg **TABLETS**

**METHYLCOBALAMIN**

- Provides neuronal protection including promoting injured nerve and axonal regeneration<sup>1</sup>
- Used for treating peripheral neuropathy with good safety<sup>1</sup>

**GABAPENTIN**

- Inhibits the release of excitatory neurotransmitters hence reduces neuropathic pain<sup>2</sup>
- Effective in reducing daily pain scores & improves the quality of sleep<sup>3</sup>

**DIABETIC NEUROPATHY**

**PERIPHERAL NEUROPATHY**

**POST-SURGICAL NEUROPATHY**

**DRUG INDUCED NEUROPATHY**

**POST HERPETIC NEURALGIA**

**Malzix<sup>®</sup>-GB100**  
Methylcobalamin 500mcg + Gabapentin 100mg **TABLETS**

1.Neural Plast. 2013; 2013: 424651.

2.Palliat Med. 2004 Jan;18(1):5-11.

3.Clin Interv Aging. 2012; 7: 249-255.



# Perfect Protein Supplement

with Full-on Health Benefits....



# Malzix®

Enriched with High Protein + Cyanocobalamin +  
**Glucosamine POWDER**

**STEVIA AS NATURAL SWEETENER**



## HIGH PROTEIN

- Promotes gain in muscle mass, especially when paired with resistance training<sup>1</sup>
- Beneficial for strength performance<sup>2</sup>

## CYANOCOBALAMIN

- Essential for DNA synthesis and for cellular energy production<sup>3</sup>

## GLUCOSAMINE

- Delays the progression and severity of OA cartilage lesions<sup>4</sup>

**MGB**  
**MZX**

**PROTEIN SUPPLEMENTATION || COMPROMISED IMMUNITY  
IN GERIATRICS & CONVALESCENCE || PHYSICAL FATIGUE AND LETHARGY  
ATHLETES AND BODY BUILDERS || AFTER PROLONGED ILLNESS**

1.J Food Sci. 2015 Mar;80 Suppl 1:A8-A15.

2.Nutrients. 2018 Sep; 10(9): 1248.

3.Nutrients. 2010 Mar; 2(3): 299–316.

4.Arthritis Res Ther. 2012; 14(1): 201.

A COMPLETE HEALTH PACK

FOR ZESTFUL LIFE...

# Oiz-Forte®

*Omega-3 Fatty Acids + Green Tea Extract + Grape Seed Extract + Ginkgo  
Biloba Extract + Ginseng + Vitamins + Minerals + Trace Elements + Antioxidants*  
**SOFTGELS**



**OMEGA-3 FATTY ACIDS:** Exerts multiple beneficial effects including anti-inflammatory actions that diminish oxidative stress<sup>1</sup>

**GREEN TEA:** Reduces the risk of stroke and coronary heart disease<sup>2</sup>

**GRAPE SEED:** Protects the cells from ROS-mediated DNA damage<sup>3</sup>

**GINKGO BILOBA:** Beneficial in alleviating symptoms of chronic fatigue syndrome (CFS)<sup>4</sup>

**GINSENG:** Reduces the fasting blood glucose or postprandial glucose in type 2 diabetic patients<sup>5</sup>

**VITAMINS + MINERALS:** Provide essential nutrients & support normal functions<sup>6</sup>

1. Med Sci Sports Exerc. 2010 Sep;42(9):1704-11.  
4. Front Nutr. 2021 Nov 26;8:658630.

2. Chin Med. 2010; 5: 13  
5. Molecules. 2019 Dec; 24(24): 4501.

3. J Food Sci Technol. 2020 Apr; 57(4): 1205-1215.  
6. Nutrients. 2019 Jan; 11(1): 101

---

**HIGH OXIDATIVE STRESS — FUNCTIONAL FATIGUE**  
**DIABETES / OBESITY / DYSLIPIDEMIA**  
**CARDIOVASCULAR COMPLICATIONS**

---



**No More Nerve  
Pain; Get  
Extreme Relief...**

**Polam<sup>®</sup>-D**

Pregabalin 75mg + Duloxetine 20mg (Delayed Release) **CAPSULES**

### **PREGABALIN**

- Well tolerated for the management of neuropathic pain<sup>1</sup>
- Improves the sleep quality in patients with PHN<sup>2</sup>

### **DULOXETINE**

- Antidepressant drug, inhibits the reuptake of serotonin & noradrenaline<sup>3</sup>
- Manages pain and mood symptoms in Fibromyalgia syndrome patients with & without major depressive disorder<sup>4</sup>

**OIZ  
PMD**

**PERIPHERAL NEUROPATHY || DIABETIC NEUROPATHY  
FIBROMYALGIA || POST-HERPETIC NEURALGIA || POST-OPERATIVE PAIN**

1. Ther Adv Drug Saf. 2014 Feb; 5(1): 38–56.

2. Medicine (Baltimore). 2017 Dec; 96(51): e9167

3. Neuropsychiatr Dis Treat. 2008 Oct; 4(5): 929–935.

4. J Pain Res. 2009; 2: 99–108.



**CURE** the Pain  
that Arises From  
Nerve Damage...



**Polam<sup>®</sup>-T**

Pregabalin 75mg + Nortriptyline 10mg **TABLETS**

**PREGABALIN**

- Used for the management of neuropathic pain<sup>1</sup>
- Relieves pain & improves pain-related sleep interference<sup>2</sup>

**NORTRIPTYLINE**

- Treats neuropathic pain and shows increased patient compliance<sup>3</sup>
- Blocks sodium channels; contributes to analgesic effects<sup>4</sup>

**PAIN ASSOCIATED WITH:**

PERIPHERAL NEUROPATHY ■ DIABETIC NEUROPATHY  
DRUG/ ALCOHOL INDUCED NEUROPATHY ■ POSTHERPETIC NEURALGIA



**Polam<sup>®</sup>**

Pregabalin 75mg + Methylcobalamin 750mcg **CAPSULES**

1. Ther Adv Drug Saf. 2014 Feb; 5(1): 38–56.  
2. Curr Neuropharmacol. 2014 Jan; 12(1): 44–56.  
3. Neural Plast. 2013; 2013: 424651.  
4. Cochrane Database Syst Rev. 2015 Jan; 2015(1): CD011209.

# The NEXT LEVEL NEUROPATHIC PAIN RELIEVER...

# Polam<sup>®</sup>-NXT

Pregabalin 75mg + Nortriptyline 10mg + Methylcobalamin 1500mcg  
**TABLETS**



**PREGABALIN:** Used for treatment of peripheral and central neuropathic pain<sup>1</sup>

**METHYLCOBALAMIN:** Promotes the regeneration of injured nerves & inhibits ectopic spontaneous discharges of injured primary sensory neurons<sup>2</sup>

#### **NORTRIPTYLINE:**

- Widely used for the treatment of neuropathic pain<sup>3</sup>
- More effective and better tolerated than amitriptyline<sup>4</sup>

## **PAIN ASSOCIATED WITH**

- **POST HERPETIC NEUROPATHY**
- **POST-SURGICAL NEUROPATHY**
- **DIABETIC NEUROPATHY**
- **DRUG INDUCED NEUROPATHY**

PMT  
PNX

1. Cochrane Database Syst Rev. 2019 Jan; 2019(1): CD007076. 2. Neural Plast. 2013; 2013: 424651.  
3. Cochrane Database Syst Rev. 2015 Jan; 2015(1): CD011209  
4. J Oral Facial Pain Headache. Winter 2019;33(1):7-13





**When Excess Fluid is  
Held in Body Tissues...**

# **TYNDR<sup>®</sup> Plus**

**Torsemide 10mg + Spironolactone 50mg TABLETS**

## **TORSEMIDE:**

- High-ceiling loop diuretic; acts on the thick ascending limb of the loop of Henle<sup>3</sup>
- Rapid onset & more predictable diuretic effect in HF patients compared to furosemide<sup>4</sup>

## **SPIRONOLACTONE:**

- First-line diuretic recommended for a patient with cirrhosis and edema<sup>1</sup>
- Reduces morbidity and mortality in severe heart failure and effectively lowers blood pressure in hypertensive patients<sup>2</sup>

**FOR TREATMENT OF RESISTANT EDEMA ASSOCIATED WITH**

**Liver Cirrhosis ■ Congestive Heart Failure**  
**Nephrotic Syndrome ■ Hypertension with Hyperaldosteronism**

# **TYNDR<sup>®</sup>-10**

**Torsemide 10mg TABLETS**


1.Int J Nephrol. 2015; 2015: 975934.

2.<https://doi.org/10.1161/01>.

3.Drugs. 1991 Jan;41(1):81-103.

4.Am Heart J. 2015 Mar; 169(3): 323-333.





**When Thyroid Gland  
is not Active Enough,  
Treat it with....**

# THYROZYTE<sup>®</sup>

Thyroxine Sodium 25, 50, 75, 100mcg

25/ 50  
75/ 100

**TABLETS**

- Synthetic T4 hormone; used to treat thyroid hormone deficiency<sup>1</sup>
- Preferred first-line treatment for primary hypothyroidism<sup>2</sup>
- Long serum half-life that permits once daily administration<sup>3</sup>
- Effective in improving cognitive function and psychological wellbeing in patients with symptoms of hypothyroidism<sup>4</sup>

**HYPOTHYROIDISM**

**PITUITARY THYROTROPIN (TSH) SUPPRESSION**

1.Eur Endocrinol. 2013 Mar; 9(1): 40–47.

2.Adv Ther. 2019; 36(Suppl 2): 30–46.

3. Thyroid. 2014 Dec 1; 24(12): 1670–1751

4.BMJ. 2001 Oct 20; 323(7318): 891–895

*For Complete Relief in  
Tough Time.....*

**Xepenta<sup>®</sup>-L**

Pantoprazole 40 mg (Enteric Coated) +  
Levosulpiride 75mg (Sustained Release) **CAPSULES**



#### **PANTOPRAZOLE**

- Helps to reduce the gastric acid secretion<sup>1</sup>
- Demonstrates a continuous improvement of the relief of symptoms and the quality of life of GERD patients<sup>2</sup>

#### **LEVOSULPIRIDE**

- Antiemetic & antidyspeptic drug<sup>3</sup>
- Effective and safe in the treatment of dyspepsia & non-erosive reflux disease<sup>4</sup>

1. Drugs. 2003;63(1):101-33. 2. Prz Gastroenterol. 2018; 13(1): 6–15.  
3. Korean J Intern Med. 1998 Feb;13(1):15-21. 4. Ther Clin Risk Manag. 2007 Mar; 3(1): 149–155.

**NON-EROSIVE REFLUX  
DISEASE**

**CHRONIC GASTRITIS**

**GASTROESOPHAGEAL  
REFLUX DISEASE**

**FUNCTIONAL DYSPEPSIA**

**SOMATOFORM DISORDERS**

**Xepenta<sup>®</sup>**  
Pantoprazole 40mg  
**TABLETS/INJECTION**





*Ease the Recurrent  
Acid Reflux  
with the Help of.....*

# Xepenta<sup>®</sup>-DSR

Pantoprazole 40mg (Enteric Coated) + **CAPSULES**  
Domperidone 30mg (Sustained Release)

## PANTOPRAZOLE

- Provides effective mucosal healing in patients with GERD and mild oesophagitis<sup>1</sup>
- Well tolerated in patients with acid-related disorders<sup>1</sup>

## DOMPERIDONE

- Blocks peripheral dopamine D2 receptors<sup>2</sup>
- Used to alleviate symptoms of nausea or vomiting<sup>2</sup>

**GERD – DYSPEPSIA – CHRONIC GASTRITIS**  
**POST-OPERATIVE NAUSEA & VOMITING**  
**NAUSEA ASSOCIATED WITH ACID PEPTIC DISORDERS**



Xepenta<sup>®</sup>

Pantoprazole 40mg TABLETS /INJECTION

1.Drugs. 2003;63(1):101-33.

2.Int J Environ Res Public Health. 2019 Aug; 16(16): 2985



Thank You  
Doctor

